ASXL1 and myelodysplastic syndrome: Similarly to DNMT3A and TET2, ASXL1 mutations were mostly studied among MDS patient cohorts, including all subtypes, finding an association with worse prognosis and a shorter OS, but no specific associations were mentioned between ASXL1 mutations and outcomes in MDS-5q cases have been described.